Poland· PL-100490389
Yorvipath
A palopegteriparatide product containing palopegteriparatidum, registered in Poland by Ascendis Pharma Bone Diseases A/S. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Palopegteriparatide is registered in 11 of 19 countries.
Countries holding a registration under ATC H05AA05 (palopegteriparatide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Palopegteriparatide · ATC H05AA05
11 / 19 countries
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Palopegteriparatidum
- Manufacturer
- Ascendis Pharma Bone Diseases A/S
- Country
- Poland (PL)
- ATC code
- H05AA05
- ATC class
- Palopegteriparatide
- Defined daily dose
- 33 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 3
- gtin05714765032453
- gtin04150188322381
- gtin05714765032323
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- BelgiumYorvipath 168 µg/0.56 mlAscendis Pharma Bone Diseases
- SpainYORVIPATH 168 MICROGRAMOS/0,56 ML SOLUCION INYECTABLE EN PLUMA PRECARGADAAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/81bda787-a3e5-4d3d-990f-9c7c4aa3de4f GET /v1/drugs/81bda787-a3e5-4d3d-990f-9c7c4aa3de4f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "420 mcg/1,4 ml",
"packaging": "05714765032453 ¦ Rpz ¦ EU/1/23/1766/003 ¦ 152238\n30 igieł ¦ 2 wstrzykiwacze 1,4 ml\n¦ UR/Z/4b/070/24 - 04150188322381 ¦ UR/Z/4b/094/26 - 04150188322381 ¦ UR/Z/4b/068/25 - 04150188322381 ¦ UR/Z/4b/162/25 - 04150188322381 ¦ UR/Z/4b/332/25 - 04150188322381 ¦ UR/Z/4b/120/26 - 05714765032323",
"substance": "Palopegteriparatidum 420 mcg/1.4 ml",
"common_name": "Palopegteriparatidum",
"pl_product_id": "100490389",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.